Generic Name: neratinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Puma

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Nerlynx is a kinase inhibitor approved for extended adjuvant (post-surgery) treatment of early breast cancer that overexpresses human epidermal growth factor receptor 2 in people who previously used Herceptin.

General Info

About 20% of breast cancers have a high level of HER2 receptors. HER2 plays a role in cell division and repair, and blocking these receptors can slow cancer growth. Studies show that taking Nerlynx after Herceptin delays recurrence or spread of early breast cancer. It was approved in 2017.


Dosing Info: Nerlynx is taken as six tablets once daily with food, usually for a year. It should be given with medications to prevent diarrhea.

Side Effects

Common side effects include diarrhea, nausea and vomiting, abdominal pain, fatigue, skin rash, mouth sores and decreased appetite. Potential serious side effects may include severe diarrhea and liver toxicity. Nerlynx should not be used during pregnancy.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: December 13, 2018